Supplementary:

Data indicators report

Hospital name: WHO Test Hospital

Country name: World Health Organization

Data from:

01 Jan 1995 to 31 Jan 1995

This is a detailed report for records with data indicators. This report, together with the full list in Excel format, is for users to check and validate records with notifiable bacteria, notifiable antibiotic-pathogen combinations, infrequent phenotypes or potential errors in the AST results at the local level. The identifiers listed include hospital number and specimen collection date. Users should not share or transfer this Supplementary data indictors report (in PDF and Excel formats) to any party outside of the hospital without data security management and confidential agreement.

Generated on: 07 Nov 2022

Content

| Summary result | 01 |
|--|----|
| Table 1: Summary of potential contaminants | 02 |
| Table 2: Summary of notifiable antibiotic-pathogen combinations | 04 |
| Table 3: Summary of infrequent phenotypes or potential errors in AST results based on | 05 |
| the indicators that the organisms are intrinsically resistant to an antibiotic but are | |
| reported as susceptible | |
| Table 4: Summary of infrequent phenotypes or potential errors in AST results based on | 14 |
| the indicators that the isolates exhibit discordant AST results | |
| Table 5: List of specimens culture positive for notifiable organisms | 15 |

Summary result

The tables are counts of records of blood samples that violated the data validation indicators stratified by the level of priority as indicated in the list_of_indicators.xlsx.

In brief, the microbiology data is de-duplicated by including only the first isolate per unique specimen number per specimen type per organism identified per evaluation period.

The microbiology_data file had:

Sample collection dates ranged from 01 Jan 1995 to 31 Jan 1995

Number of records of all specimen types collected within the above date range:

622 records

Number of records of all specimen types with culture positive for a microorganism:

622 records

Number of records of blood specimens collected within the above date range:

81 records

Number of records of blood specimens with culture positive for a microorganism:

81 records

Number of records of blood specimens with no growth for a microorganism:

0 records

| Organisms | Proportion of blood samples (n) |
|---|---------------------------------|
| Arcanobacterium spp. | NA |
| Arthrobacter spp. | NA |
| Bacillus spp. except Bacillus anthracis | NA |
| Brevibacillus spp. | NA |
| Brevibacterium spp. | NA |
| Cellulomonas spp. | NA |
| Cellulosimicrobium spp. | NA |
| Corynebacterium spp. except Corynebacterium diphtheriae, Corynebacterium jeikeium, Corynebacterium pseudotuberculosis, Corynebacterium striatum, Corynebacterium ulcerans, and Corynebacterium urealyticum | NA |
| Cutibacterium spp. | NA |
| Dermabacter spp. | NA |
| Dermacoccus spp. | NA |
| Diphtheroids spp. | NA |
| Exiguobacterium spp. | NA |
| Geobacillus spp. | NA |
| Helcobacillus spp. | NA |
| Janibacter spp. | NA |
| Knoellia spp. | NA |
| Kocuria spp. | NA |
| Kytococcus spp. | NA |
| Leifsonia spp. | NA |
| Microbacterium spp. | NA |
| Micrococcus spp. | NA |
| Nesterenkonia spp. | NA |
| Paenibacillus spp. | NA |
| Propionibacterium spp. | NA |
| Pseudoclavibacter spp. | NA |
| Staphylococcus spp. except Staphylococcus aureus, and Staphylococcus lugdunensis | NA |
| Trueperella spp. | NA |
| Virgibacillus spp. | NA |
| Viridans group streptococci include Streptococcus anginosus, Streptococcus bovis, Streptococcus constellatus, Streptococcus gallolyticus, Streptococcus gordonii, Streptococcus intermedius, Streptococcus mitis, Streptococcus mutans, Streptococcus oralis, Streptococcus salivarius, Streptococcus sanguinis, and Streptococcus vestibularis | NA |

Blood culture contamination rate is defined as the number of raw contaminated cultures per number of blood cultures received by the laboratory per reporting period. Blood culture contamination rate will not be estimated in case that the data of negative culture (specified as 'no growth' in the dictionary_for_microbiology_data file) is not available. Details of the criteria are available in "list_of_indicators.xlsx" in the folder "Configuration".

Table 1 (continue): Summary of potential contaminants

| Organisms | Proportion of blood samples (n) | |
|--------------------|---------------------------------|--|
| Other contaminants | NA | |

Blood culture contamination rate is defined as the number of raw contaminated cultures per number of blood cultures received by the laboratory per reporting period. Blood culture contamination rate will not be estimated in case that the data of negative culture (specified as 'no growth' in the dictionary_for_microbiology_data file) is not available. Details of the criteria are available in "list_of_indicators.xlsx" in the folder "Configuration".

Table 2: Summary of notifiable antibiotic-pathogen combinations

| Organisms | Antimicrobial-susceptible profile | Proportion of blood samples (n) |
|-------------------------|-----------------------------------|---------------------------------|
| Acinetobacter baumannii | Carbapenems-NS | NA |
| Pseudomonas aeruginosa | Carbapenems-NS | NA |
| Enterobacteriaceae | Carbapenems-NS | NA |
| Enterobacteriaceae | 3GC-NS | NA |
| Enterobacteriaceae | Carbapenem-S and 3GC-NS | NA |
| Enterococcus faecium | Vancomycin-NS | NA |
| Staphylococcus aureus | Vancomycin-NS | NA |
| Staphylococcus aureus | Methicillin-NS | NA |
| Helicobacter pylori | Clarithromycin-NS | NA |
| Campylobacter spp. | Fluoroquinolones-NS | NA |
| Salmonella spp. | Fluoroquinolones-NS | NA |
| Neisseria gonorrhoeae | 3GC-NS | NA |
| Neisseria gonorrhoeae | Fluoroquinolones-NS | NA |
| Neisseria gonorrhoeae | Fluoroquinolones-NS and 3GC-S | NA |

Notifiable antibiotic-pathogen combinations and their classifications are defined as WHO list of AMR priority pathogen published in 2017 [1]. The proportion represents the number of patients with blood culture positive for non-susceptible isolates (numerator) over the total number of patient with blood culture positive and AST result available in the raw microbiology data (denominator). Details of the criteria are available in "list_of_indicators.xlsx" in the folder "Configuration". NS=Non-susceptible; 3GC-NS=3rd-generation cephalosporin; Carbapenems-NS: imipenem, meropenem, ertapenem or doripenem; Fluoroquinolones-NS: ciprofloxacin or levofloxacin; Methicillin: methicillin, oxacillin, or cefoxitin

^[1] World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research discover, and development of new antibiotics. 2017.

https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf. accessed 7th December 2021.

Table 3: Summary of infrequent phenotypes or potential errors in AST results based on the indicators that the organisms are intrinsically resistant to an antibiotic but are reported as susceptible

| Organisms | Antibiotic that intrinsically resistant but reported as susceptible | Proportion of blood samples (n) |
|----------------------------|---|---------------------------------|
| Achromobacter xylosoxidans | Amoxicillin | NA |
| Achromobacter xylosoxidans | Ampicillin | NA |
| Achromobacter xylosoxidans | Aztreonam | NA |
| Achromobacter xylosoxidans | Ceftriaxone | NA |
| Achromobacter xylosoxidans | Doxycycline | NA |
| Achromobacter xylosoxidans | Ertapenem | NA |
| Achromobacter xylosoxidans | Fosfomycin | NA |
| Achromobacter xylosoxidans | Tetracycline | NA |
| Achromobacter xylosoxidans | Trimethoprim | NA |
| Acinetobacter baumannii | Amoxicillin and clavulanic acid | NA |
| Acinetobacter baumannii | Amoxicillin | NA |
| Acinetobacter baumannii | Ampicillin | NA |
| Acinetobacter baumannii | Aztreonam | NA |
| Acinetobacter baumannii | Ceftriaxone | NA |
| Acinetobacter baumannii | Doxycycline | NA |
| Acinetobacter baumannii | Ertapenem | NA |
| Acinetobacter baumannii | Fosfomycin | NA |
| Acinetobacter baumannii | Tetracycline | NA |
| Acinetobacter baumannii | Trimethoprim | NA |
| Acinetobacter nosocomialis | Ceftriaxone | NA |
| Acinetobacter nosocomialis | Amoxicillin | NA |
| Acinetobacter nosocomialis | Amoxicillin and clavulanic acid | NA |
| Acinetobacter nosocomialis | Ampicillin | NA |
| Acinetobacter nosocomialis | Aztreonam | NA |
| Acinetobacter nosocomialis | Doxycycline | NA |
| Acinetobacter nosocomialis | Ertapenem | NA |
| Acinetobacter nosocomialis | Fosfomycin | NA |
| Acinetobacter nosocomialis | Tetracycline | NA |
| Acinetobacter nosocomialis | Trimethoprim | NA |
| Acinetobacter pittii | Ceftriaxone | NA |

Table 3 (continue): Summary of infrequent phenotypes or potential errors in AST results based on the indicators that the organisms are intrinsically resistant to an antibiotic but are reported as susceptible

| Organisms | Antibiotic that intrinsically resistant but reported as susceptible | Proportion of blood samples (n) |
|------------------------------|---|---------------------------------|
| Acinetobacter pittii | Amoxicillin | NA |
| Acinetobacter pittii | Amoxicillin and clavulanic acid | NA |
| Acinetobacter pittii | Ampicillin | NA |
| Acinetobacter pittii | Aztreonam | NA |
| Acinetobacter pittii | Doxycycline | NA |
| Acinetobacter pittii | Ertapenem | NA |
| Acinetobacter pittii | Fosfomycin | NA |
| Acinetobacter pittii | Tetracycline | NA |
| Acinetobacter pittii | Trimethoprim | NA |
| Aeromonas caviae | Amoxicillin | NA |
| Aeromonas caviae | Ampicillin | NA |
| Aeromonas caviae | Ampicillin and sulbactam | NA |
| Aeromonas dhakensis | Amoxicillin | NA |
| Aeromonas dhakensis | Ampicillin | NA |
| Aeromonas dhakensis | Ampicillin and sulbactam | NA |
| Aeromonas dhakensis | Cefoxitin | NA |
| Aeromonas hydrophila | Amoxicillin | NA |
| Aeromonas hydrophila | Ampicillin | NA |
| Aeromonas hydrophila | Ampicillin and sulbactam | NA |
| Aeromonas veronii | Amoxicillin | NA |
| Aeromonas veronii | Ampicillin | NA |
| Aeromonas veronii | Ampicillin and sulbactam | NA |
| Aeromonas veronii | Ticarcillin | NA |
| Burkholderia cepacia complex | Ampicillin | NA |
| Burkholderia cepacia complex | Aminoglycosides | NA |
| Burkholderia cepacia complex | Amoxicillin | NA |
| Burkholderia cepacia complex | Amoxicillin and clavulanic acid | NA |
| Burkholderia cepacia complex | Ampicillin and sulbactam | NA |
| Burkholderia cepacia complex | Aztreonam | NA |
| Burkholderia cepacia complex | Ceftriaxone | NA |

Table 3 (continue): Summary of infrequent phenotypes or potential errors in AST results based on the indicators that the organisms are intrinsically resistant to an antibiotic but are reported as susceptible

| Organisms | Antibiotic that intrinsically resistant but reported as susceptible | Proportion of blood samples (n) |
|------------------------------|---|---------------------------------|
| Burkholderia cepacia complex | Chloramphenicol | NA |
| Burkholderia cepacia complex | Ciprofloxacin | NA |
| Burkholderia cepacia complex | Colistin | NA |
| Burkholderia cepacia complex | Ertapenem | NA |
| Burkholderia cepacia complex | Fosfomycin | NA |
| Burkholderia cepacia complex | Piperacillin | NA |
| Burkholderia cepacia complex | Piperacillin and tazobactam | NA |
| Burkholderia cepacia complex | Ticarcillin | NA |
| Burkholderia cepacia complex | Ticarcillin and clavulanic acid | NA |
| Burkholderia cepacia complex | Trimethoprim | NA |
| Citrobacter amalonaticus | Amoxicillin | NA |
| Citrobacter amalonaticus | Ampicillin | NA |
| Citrobacter freundii | Amoxicillin and clavulanic acid | NA |
| Citrobacter freundii | Amoxicillin | NA |
| Citrobacter freundii | Ampicillin | NA |
| Citrobacter freundii | Ampicillin and sulbactam | NA |
| Citrobacter freundii | Cefadroxil | NA |
| Citrobacter freundii | Cefalexin | NA |
| Citrobacter freundii | Cefazolin | NA |
| Citrobacter freundii | Cefoxitin | NA |
| Citrobacter freundii | Cephalothin | NA |
| Citrobacter koseri | Amoxicillin | NA |
| Citrobacter koseri | Ampicillin | NA |
| Elizabethkingia anophelis | Ampicillin | NA |
| Elizabethkingia anophelis | Amoxicillin | NA |
| Elizabethkingia anophelis | Amoxicillin and clavulanic acid | NA |
| Elizabethkingia anophelis | Ampicillin and sulbactam | NA |
| Elizabethkingia anophelis | Aztreonam | NA |
| Elizabethkingia anophelis | Cefepime | NA |
| Elizabethkingia anophelis | Ceftazidime | NA |

Table 3 (continue): Summary of infrequent phenotypes or potential errors in AST results based on the indicators that the organisms are intrinsically resistant to an antibiotic but are reported as susceptible

| Organisms | Antibiotic that intrinsically resistant but reported as susceptible | Proportion of blood samples (n) |
|--------------------------------|---|---------------------------------|
| Elizabethkingia anophelis | Ceftriaxone | NA |
| Elizabethkingia anophelis | Ertapenem | NA |
| Elizabethkingia anophelis | Imipenem | NA |
| Elizabethkingia anophelis | Meropenem | NA |
| Elizabethkingia anophelis | Ticarcillin | NA |
| Elizabethkingia anophelis | Ticarcillin and clavulanic acid | NA |
| Elizabethkingia meningoseptica | Ampicillin | NA |
| Elizabethkingia meningoseptica | Amoxicillin | NA |
| Elizabethkingia meningoseptica | Amoxicillin and clavulanic acid | NA |
| Elizabethkingia meningoseptica | Ampicillin and sulbactam | NA |
| Elizabethkingia meningoseptica | Aztreonam | NA |
| Elizabethkingia meningoseptica | Cefepime | NA |
| Elizabethkingia meningoseptica | Ceftazidime | NA |
| Elizabethkingia meningoseptica | Ceftriaxone | NA |
| Elizabethkingia meningoseptica | Colistin | NA |
| Elizabethkingia meningoseptica | Ertapenem | NA |
| Elizabethkingia meningoseptica | Imipenem | NA |
| Elizabethkingia meningoseptica | Meropenem | NA |
| Elizabethkingia meningoseptica | Ticarcillin | NA |
| Elizabethkingia meningoseptica | Ticarcillin and clavulanic acid | NA |
| Enterobacter cloacae complex | Amoxicillin | NA |
| Enterobacter cloacae complex | Amoxicillin and clavulanic acid | NA |
| Enterobacter cloacae complex | Ampicillin | NA |
| Enterobacter cloacae complex | Ampicillin and sulbactam | NA |
| Enterobacter cloacae complex | Cefadroxil | NA |
| Enterobacter cloacae complex | Cefalexin | NA |
| Enterobacter cloacae complex | Cefazolin | NA |
| Enterobacter cloacae complex | Cefoxitin | NA |
| Enterobacter cloacae complex | Cephalothin | NA |
| Enterococcus casseliflavus | Vancomycin | NA |

Table 3 (continue): Summary of infrequent phenotypes or potential errors in AST results based on the indicators that the organisms are intrinsically resistant to an antibiotic but are reported as susceptible

| Organisms | Antibiotic that intrinsically resistant but reported as susceptible | Proportion of blood samples (n) |
|-------------------------|---|---------------------------------|
| Enterococcus faecalis | Ceftazidime | NA |
| Enterococcus faecalis | Aminoglycosides | NA |
| Enterococcus faecalis | Ceftazidime | NA |
| Enterococcus faecalis | 3GC | NA |
| Enterococcus faecalis | Clindamycin | NA |
| Enterococcus faecalis | Fusidic acid | NA |
| Enterococcus faecium | Macrolides | NA |
| Enterococcus faecium | Dalfopristin and quinupristin | NA |
| Enterococcus faecium | Sulfonamides | NA |
| Enterococcus gallinarum | Vancomycin | NA |
| Escherichia hermannii | Ampicillin | NA |
| Escherichia hermannii | Ticarcillin | NA |
| Hafnia alvei | Amoxicillin | NA |
| Hafnia alvei | Amoxicillin and clavulanic acid | NA |
| Hafnia alvei | Ampicillin | NA |
| Hafnia alvei | Colistin | NA |
| Klebsiella aerogenes | Amoxicillin | NA |
| Klebsiella aerogenes | Amoxicillin and clavulanic acid | NA |
| Klebsiella aerogenes | Ampicillin | NA |
| Klebsiella aerogenes | Ampicillin and sulbactam | NA |
| Klebsiella aerogenes | Cefadroxil | NA |
| Klebsiella aerogenes | Cefalexin | NA |
| Klebsiella aerogenes | Cefazolin | NA |
| Klebsiella aerogenes | Cefoxitin | NA |
| Klebsiella aerogenes | Cephalothin | NA |
| Klebsiella oxytoca | Amoxicillin | NA |
| Klebsiella oxytoca | Ampicillin | NA |
| Klebsiella pneumoniae | Amoxicillin | NA |
| Klebsiella pneumoniae | Ampicillin | NA |
| Klebsiella variicola | Amoxicillin | NA |

Table 3 (continue): Summary of infrequent phenotypes or potential errors in AST results based on the indicators that the organisms are intrinsically resistant to an antibiotic but are reported as susceptible

| Organisms | Antibiotic that intrinsically resistant but reported as susceptible | Proportion of blood samples (n) |
|--------------------------|---|---------------------------------|
| Klebsiella variicola | Ampicillin | NA |
| Leclercia adecarboxylata | Fosfomycin | NA |
| Morganella morganii | Amoxicillin | NA |
| Morganella morganii | Amoxicillin and clavulanic acid | NA |
| Morganella morganii | Ampicillin | NA |
| Morganella morganii | Cefadroxil | NA |
| Morganella morganii | Cefalexin | NA |
| Morganella morganii | Cefazolin | NA |
| Morganella morganii | Cephalothin | NA |
| Morganella morganii | Colistin | NA |
| Morganella morganii | Nitrofurantoin | NA |
| Morganella morganii | Tetracyclines | NA |
| Ochrobactrum anthropi | Ampicillin | NA |
| Ochrobactrum anthropi | Amoxicillin | NA |
| Ochrobactrum anthropi | Amoxicillin and clavulanic acid | NA |
| Ochrobactrum anthropi | Ampicillin and sulbactam | NA |
| Ochrobactrum anthropi | Aztreonam | NA |
| Ochrobactrum anthropi | Cefepime | NA |
| Ochrobactrum anthropi | Ceftazidime | NA |
| Ochrobactrum anthropi | Ceftriaxone | NA |
| Ochrobactrum anthropi | Ertapenem | NA |
| Ochrobactrum anthropi | Piperacillin | NA |
| Ochrobactrum anthropi | Piperacillin and tazobactam | NA |
| Ochrobactrum anthropi | Ticarcillin | NA |
| Ochrobactrum anthropi | Ticarcillin and clavulanic acid | NA |
| Proteus mirabilis | Colistin | NA |
| Proteus mirabilis | Nitrofurantoin | NA |
| Proteus mirabilis | Tetracyclines | NA |
| Proteus mirabilis | Tigecycline | NA |
| Proteus penneri | Amoxicillin | NA |

Table 3 (continue): Summary of infrequent phenotypes or potential errors in AST results based on the indicators that the organisms are intrinsically resistant to an antibiotic but are reported as susceptible

| Organisms | Antibiotic that intrinsically resistant but reported as susceptible | Proportion of blood samples (n) |
|------------------|---|---------------------------------|
| Proteus penneri | Ampicillin | NA |
| Proteus penneri | Cefadroxil | NA |
| Proteus penneri | Cefalexin | NA |
| Proteus penneri | Cefazolin | NA |
| Proteus penneri | Cefuroxime | NA |
| Proteus penneri | Cephalothin | NA |
| Proteus penneri | Colistin | NA |
| Proteus penneri | Nitrofurantoin | NA |
| Proteus penneri | Tetracyclines | NA |
| Proteus penneri | Tigecycline | NA |
| Proteus rettgeri | Amoxicillin | NA |
| Proteus rettgeri | Amoxicillin and clavulanic acid | NA |
| Proteus rettgeri | Ampicillin | NA |
| Proteus rettgeri | Ampicillin and sulbactam | NA |
| Proteus rettgeri | Cefadroxil | NA |
| Proteus rettgeri | Cefalexin | NA |
| Proteus rettgeri | Cefazolin | NA |
| Proteus rettgeri | Cephalothin | NA |
| Proteus rettgeri | Colistin | NA |
| Proteus rettgeri | Nitrofurantoin | NA |
| Proteus rettgeri | Tetracyclines | NA |
| Proteus stuartii | Amoxicillin and clavulanic acid | NA |
| Proteus stuartii | Amoxicillin | NA |
| Proteus stuartii | Ampicillin | NA |
| Proteus stuartii | Ampicillin and sulbactam | NA |
| Proteus stuartii | Cefadroxil | NA |
| Proteus stuartii | Cefalexin | NA |
| Proteus stuartii | Cefazolin | NA |
| Proteus stuartii | Cephalothin | NA |
| Proteus stuartii | Colistin | NA |

Created on: 07 Nov 2022

Table 3 (continue): Summary of infrequent phenotypes or potential errors in AST results based on the indicators that the organisms are intrinsically resistant to an antibiotic but are reported as susceptible

| Organisms | Antibiotic that intrinsically resistant but reported as susceptible | Proportion of blood samples (n) |
|------------------------|---|---------------------------------|
| Proteus stuartii | Gentamicin | NA |
| Proteus stuartii | Nitrofurantoin | NA |
| Proteus stuartii | Tetracyclines | NA |
| Proteus vulgaris | Ampicillin | NA |
| Proteus vulgaris | Amoxicillin | NA |
| Proteus vulgaris | Cefadroxil | NA |
| Proteus vulgaris | Cefalexin | NA |
| Proteus vulgaris | Cefazolin | NA |
| Proteus vulgaris | Cefuroxime | NA |
| Proteus vulgaris | Cephalothin | NA |
| Proteus vulgaris | Colistin | NA |
| Proteus vulgaris | Nitrofurantoin | NA |
| Proteus vulgaris | Tetracyclines | NA |
| Proteus vulgaris | Tigecycline | NA |
| Pseudomonas aeruginosa | Ampicillin | NA |
| Pseudomonas aeruginosa | Amoxicillin | NA |
| Pseudomonas aeruginosa | Amoxicillin and clavulanic acid | NA |
| Pseudomonas aeruginosa | Ampicillin and sulbactam | NA |
| Pseudomonas aeruginosa | Ceftriaxone | NA |
| Pseudomonas aeruginosa | Chloramphenicol | NA |
| Pseudomonas aeruginosa | Ertapenem | NA |
| Pseudomonas aeruginosa | Kanamycin | NA |
| Pseudomonas aeruginosa | Neomycin | NA |
| Pseudomonas aeruginosa | Tigecycline | NA |
| Pseudomonas aeruginosa | Trimethoprim | NA |
| Raoultella spp. | Amoxicillin | NA |
| Raoultella spp. | Ampicillin | NA |
| Raoultella spp. | Ticarcillin | NA |
| Serratia marcescens | Amoxicillin and clavulanic acid | NA |
| Serratia marcescens | Amoxicillin | NA |

Page 12

Created on: 07 Nov 2022

Table 3 (continue): Summary of infrequent phenotypes or potential errors in AST results based on the indicators that the organisms are intrinsically resistant to an antibiotic but are reported as susceptible

| Organisms | Antibiotic that intrinsically resistant but reported as susceptible | Proportion of blood samples (n) | |
|-----------------------------|---|---------------------------------|--|
| Serratia marcescens | Ampicillin | NA | |
| Serratia marcescens | Ampicillin and sulbactam | NA | |
| Serratia marcescens | Cefadroxil NA | | |
| Serratia marcescens | Cefalexin NA | | |
| Serratia marcescens | Cefazolin NA | | |
| Serratia marcescens | Cefoxitin | Cefoxitin NA | |
| Serratia marcescens | Cefuroxime | NA | |
| Serratia marcescens | Cephalothin | NA | |
| Serratia marcescens | Colistin | NA | |
| Serratia marcescens | Nitrofurantoin | NA | |
| Serratia marcescens | Tetracyclines | NA | |
| Yersinia enterocolitica | Amoxicillin | NA | |
| Yersinia enterocolitica | Amoxicillin and clavulanic acid | NA | |
| Yersinia enterocolitica | Ampicillin | NA | |
| Yersinia enterocolitica | Ampicillin and sulbactam | NA | |
| Yersinia enterocolitica | Cefadroxil | NA | |
| Yersinia enterocolitica | Cefalexin | NA | |
| Yersinia enterocolitica | Cefazolin | NA | |
| Yersinia enterocolitica | Cefoxitin | NA | |
| Yersinia enterocolitica | Cephalothin | NA | |
| Yersinia enterocolitica | Ticarcillin | NA | |
| Yersinia pseudotuberculosis | Colistin NA | | |

Table 4: Summary of infrequent phenotypes or potential errors in AST results based on the indicators that the isolates exhibit discordant AST results

| Organisms | Antibiotic class that the isolates exhibit discordant AST results | Proportion of blood samples (n) |
|------------------------|---|---------------------------------|
| All | Penicillins, Betalactam combinations* | NA |
| All | Penicillins** | NA |
| All | Quinolones, Fluoroquinolones*** | NA |
| Enterobacteriaceae | Aminoglycosides**** | NA |
| Enterobacteriaceae | Cephems**** | NA |
| Pseudomonas aeruginosa | Aminoglycosides**** | NA |

^{*}The numerator counts the number of isolates that exhibit discordant AST results between penicillin and beta-lactam combinations. For example, an isolate which is reported as susceptible to amoxicillin but non-susceptible to amoxicillin/clavulanic acid.

^{**}The numerator counts the number of isolates that exhibit discordant AST results in penicillin antibiotics. For example, an isolate which is reported as is susceptible to ampicillin/sulbactam but non-susceptible to piperacillin/tazobactam OR ticarcillin/clavulanic acid.

^{***}The numerator counts the number of isolates that exhibit discordant AST results between quinolone and fluoroquinolone. For example, an isolate which is reported as susceptible to nalidixic acid but non-susceptible to fluoroquinolones.

^{****}The numerator counts the number of Enterobacteriaceae or *P. aeruginosa* isolates that exhibit discordant AST in aminoglycosides. For example, an Enterobacteriaceae isolate which is reported as non-susceptible to amikacin but susceptible to gentamicin, netilmicin, or tobramycin.

^{*****}The numerator counts the number of Enterobacteriaceae isolates that exhibit discordant AST in cephems. For example, an Enterobacteriaceae isolate which is reported as susceptible to first generation cephalosporin or second-generation cephalosporin, but non-susceptible to third-generation cephalosporin.

Table 5: List of specimens culture positive for notifiable organisms

| Hospital number | Specimen collection date | Specimen type | Organisms |
|-----------------|--------------------------|---------------|------------------------|
| _3351596206_ | 11 Jan 1995 | Others | Neisseria meningitidis |
| _3491549456_ | 17 Jan 1995 | Others | Neisseria meningitidis |

 $^{^{\}star}\text{CSF} = \text{Cerebrospinal fluid}; \ \text{RTS} = \text{Respiratory tract specimens}; \ \text{Others} = \text{Others sample types}$